CompletedNot applicable

Naturalistic Study of Microdosing With Psilocybin

NCT05160220 · NATMICRO · National Council of Scientific and Technical Research, Argentina

Closed to entry

Status

Not accepting participants

Not applicable

Phase

Target enrolment

Study sites

Outside the US

What it is testing

Summary

This study seeks to understand the neural, cognitive and behavioral effects of low doses of psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis) consumed in natural settings following a placebo-controlled double-blind experimental design.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Resting state oscillations measured with EEG
Measured over 1 week
Attention
Measured over 1 week
Inhibitory control
Measured over 1 week
Conscious access
Measured over 1 week
Visual perception
Measured over 1 week
Physical activity
Measured over 1 week
Divergent thinking
Measured over 1 week
Attention
Measured over 1 week
Cognitive flexibility
Measured over 1 week
Convergent thinking
Measured over 1 week
Convergent thinking
Measured over 1 week

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

21 Years

Ages

All

Sex

Accepted

Healthy volunteers

Inclusion Criteria: 1. Men and woman with more than 21 years. 2. Participans are planning to microdose using their own dried mushroom material and adhere to the experimental protocol. 3. No active psychiatric conditions requiring treatment with psychotropic medications. 4. Able to provide informed consent. Excusion Criteria: 1. Use of psychotropic medication during the study, including stimulants such as caffeine. 2. Prior adverse reactions to psychedelics according to the Challenging Experiences Questionnaire administered during initial screening. 3. Pregnant women or women during lactation 4. History of high or low blood pressure or other cardiovascular risks.

Where

1 study site

Facility	City	Region	Country
Instituto de Fisica de Buenos Aires (IFIBA)	Buenos Aires	—	Argentina

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05160220 on ClinicalTrials.gov →

Last updated in the registry 2021-12-16. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Psilocybin

Indication